CHE (Chemed Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by CHE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2026-08-24 | SPENCER S LEE | executive vice president | Sell | — | — |
| 2026-08-10 | Brian C Judkins | VP and Chief Legal Officer | MIXED | — | — |
| 2026-08-06 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | — | — |
| 2026-08-06 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | — | — |
| 2026-08-04 | KEVIN J MCNAMARA | president and CEO | MIXED | — | — |
| 2026-08-03 | PATRICK P GRACE | Director | Sell | — | — |
| 2026-06-10 | ANDREA R LINDELL | Director | Sell | — | — |
| 2026-05-29 | GEORGE J WALSH III | Director | Sell | — | — |
| 2026-05-19 | Ron DeLyons | Director | A | — | — |
| 2026-05-19 | PATRICK P GRACE | Director | A | — | — |
| 2026-05-19 | Christopher J Heaney | Director | A | — | — |
| 2026-05-19 | ANDREA R LINDELL | Director | A | — | — |
| 2026-05-19 | Eileen P McCarthy | Director | A | — | — |
| 2026-05-19 | John Meredith Mount Jr. | Director | A | — | — |
| 2026-05-19 | GEORGE J WALSH III | Director | A | — | — |
| 2026-05-08 | PATRICK P GRACE | Director | Sell | — | — |
| 2026-05-04 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2026-03-30 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2026-03-13 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2026-02-17 | Brian C Judkins | VP and Chief Legal Officer | MIXED | — | — |
| 2026-02-17 | KEVIN J MCNAMARA | president and CEO | MIXED | — | — |
| 2026-02-17 | Michael D Witzeman | VP & Chief Financial Officer | MIXED | — | — |
| 2026-02-17 | Joel L Wherley | CEO - Vitas Healthcare | MIXED | — | — |
| 2026-02-17 | THOMAS C HUTTON | vice president | MIXED | — | — |
| 2026-02-17 | SPENCER S LEE | executive vice president | MIXED | — | — |
| 2025-12-29 | ANDREA R LINDELL | Director | G | — | — |
| 2025-11-25 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2025-11-19 | SPENCER S LEE | executive vice president | G | — | — |
| 2025-10-22 | KEVIN J MCNAMARA | president and CEO | A | — | — |
| 2025-10-22 | THOMAS C HUTTON | vice president | A | — | — |
| 2025-10-22 | Michael D Witzeman | VP & Chief Financial Officer | A | — | — |
| 2025-10-22 | Brian C Judkins | VP and Chief Legal Officer | A | — | — |
| 2025-10-22 | SPENCER S LEE | executive vice president | A | — | — |
| 2025-10-22 | Joel L Wherley | CEO - Vitas Healthcare | A | — | — |
| 2025-09-29 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2025-09-10 | PATRICK P GRACE | Director | Sell | — | — |
| 2025-08-05 | Nicholas Michael Westfall | Executive Vice President | Sell | — | — |
| 2025-08-05 | GEORGE J WALSH III | Director | Buy | — | — |
| 2025-08-05 | KEVIN J MCNAMARA | president and CEO | Sell | — | — |
| 2025-05-20 | Ron DeLyons | Director | A | — | — |
| 2025-05-20 | PATRICK P GRACE | Director | A | — | — |
| 2025-05-20 | Christopher J Heaney | Director | A | — | — |
| 2025-05-20 | ANDREA R LINDELL | Director | A | — | — |
| 2025-05-20 | Eileen P McCarthy | Director | A | — | — |
| 2025-05-20 | John Meredith Mount Jr. | Director | A | — | — |
| 2025-05-20 | GEORGE J WALSH III | Director | A | — | — |
| 2025-05-19 | SPENCER S LEE | executive vice president | Sell | — | — |
| 2025-05-12 | Nicholas Michael Westfall | Executive Vice President | MIXED | — | — |
| 2025-05-08 | SPENCER S LEE | executive vice president | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | chairman of the board | 148,594 | — |
| — | Director | 144,335 | — |
| — | president and CEO | 70,418 | — |
| — | vice president | 38,381 | — |
| — | Director | 29,719 | — |
| — | executive vice president | 22,508 | — |
| — | Director | 22,000 | — |
| — | executive vice president | 13,912 | — |
| — | Director | 9,318 | — |
| — | VP and Chief Legal Officer | 9,222 | — |
| — | VP & Chief Financial Officer | 6,073 | — |
| — | Director | 6,028 | — |
| — | executive vice president & CFO | 5,826 | — |
| — | Director | 5,593 | — |
| — | Director | 4,578 | — |
| — | Director | 3,643 | — |
| — | Director | 3,533 | — |
| — | Director | 2,775 | — |
| — | VP and Chief Legal Officer | 2,347 | — |
| — | Director | 2,052 | — |
| — | vice president & controller | 1,800 | — |
| — | Director | 1,457 | — |
| — | Director | 1,316 | — |
| — | Director | 1,241 | — |
| — | CEO - Vitas Healthcare | 1,181 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CHE quote page; the site-wide leaderboard is on the insider transactions hub.